Sutro Biopharma Receives FDA Clearance for STRO-004 Tissue Factor ADC, Advances Dual-Payload Platform
核心洞察
Sutro Biopharma received U.S. FDA clearance for its IND application for STRO-004, a potential best-in-class Tissue Factor (搜索) ADC, with first patient dosing expected before year-end.
The company demonstrated favorable preclinical safety data for STRO-004 in non-human primate studies up to 50 mg/kg, the highest dose tested.
Sutro's dual-payload ADC collaboration with Astellas progresses with one program entering IND-enabling toxicology studies in Q1 2025.
Sutro Biopharma has achieved a significant regulatory milestone with U.S. FDA clearance of its Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor (搜索) antibody-drug conjugate (ADC). The company expects to dose the first patient in a first-in-human basket trial before year-end, ahead of original projections.
Strong Preclinical Safety Profile Supports Clinical Advancement
STRO-004 demonstrated a favorable preclinical safety profile in non-human primate studies, with testing conducted up to 50 mg/kg, representing the highest dose evaluated. This safety data supports the therapeutic potential of Sutro's next-generation Tissue Factor (搜索)-targeting exatecan ADC as it enters clinical development.
"STRO-004, our Tissue Factor (搜索) ADC, has received IND clearance ahead of our projections and remains on track to enter the clinic this year, backed by compelling preclinical data that highlight its strong safety profile and potential best-in-class differentiation," said Jane Chung, Sutro's Chief Executive Officer.
Dual-Payload ADC Platform Gains Momentum
Sutro continues to advance its innovative dual-payload ADC technology through both wholly owned programs and strategic collaborations. The company's collaboration with Astellas focuses on developing dual-payload immunostimulatory ADCs (iADCs) that combine cytotoxic payloads with novel immunostimulatory payloads, designed to enhance therapeutic index and overcome tumor resistance.
Two research and development programs are progressing under the Astellas collaboration, with one program entering an IND-enabling toxicology study in the first quarter of 2025. Sutro's wholly owned dual-payload ADC program remains on track with an IND submission targeted for 2027.
Expanding Pipeline with STRO-006
The company's pipeline includes STRO-006 (搜索), a highly selective integrin β6 (搜索) (ITGB6 (搜索)) ADC expected to enter clinical development in 2026 for treating multiple solid tumors. This addition further strengthens Sutro's portfolio of next-generation ADCs targeting large oncology markets with limited treatment options.
Scientific Leadership Demonstrated at Key Conferences
At the 16th Annual World ADC Conference in November 2025, Sutro conducted five presentations and participated in three panel sessions, demonstrating continued leadership in ADC innovation. The company also presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlighting preclinical results showing how novel immunostimulatory dual-payload ADCs can enhance therapeutic index and overcome patient resistance.
Financial Position Supports Strategic Focus
Following organizational restructuring announced in September 2025, Sutro reported cash, cash equivalents and marketable securities of $167.6 million as of September 30, 2025, compared to $388.3 million in the prior year period. The restructuring, combined with expected near-term milestone payments, extends the company's cash runway into at least mid-2027.
Third quarter 2025 revenue reached $9.7 million, compared to $8.5 million in the same period of 2024, with the 2025 amount related principally to the Astellas collaboration. Total R&D and G&A expenses decreased to $48.6 million from $76.4 million in the comparable 2024 period, reflecting operational efficiencies from the restructuring.
"Following our recent organizational restructuring, we are well positioned to focus resources on the programs and partnerships that offer the greatest potential for near-term value creation," Chung noted. "The resulting operational efficiencies, combined with expected near-term milestone payments, extend our cash runway into at least mid-2027—allowing us to advance key programs through meaningful clinical milestones."
Technology Platform Designed for Enhanced Efficacy
Sutro's cell-free platform produces ADCs engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. By fully optimizing the antibody, linker, and payload components, the company's next-generation ADC platform aims to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for cancer patients.
The company plans to host a virtual R&D Day on November 12, 2025, featuring presentations from Sutro management and guest speakers to provide updates on its next-generation ADC programs.